siRNA (short interfering RNA) is a type of RNA molecule that can silence the expression of specific genes by interfering with their translation into proteins. The mechanism reaches transcripts that small molecules handle poorly. Programs still run into delivery, stability, specificity, and toxicity problems with siRNA molecules in vivo. To work through them, researchers need to understand how siRNA molecules behave and interact with different biological systems in the body. That is where DMPK (drug metabolism and pharmacokinetics) research comes in.
Where siRNA DMPK Work Gets Difficult
DMPK is the study of how drugs are absorbed, distributed, metabolized, and excreted by the body. For an oligonucleotide the questions are narrower than for a small molecule: how much of the dose reaches the tissue that expresses the target, how long the molecule survives contact with nucleases, and whether the chemistry added to stabilize it also changes where it ends up. DMPK research answers those questions, and the answers are what allow a team to optimize the design, delivery, and dosing of siRNA molecules while keeping adverse effects in check.
Species differences complicate the work. Physiological and biochemical characteristics vary enough between animals that a result in one model does not carry automatically to another, so the choice of animal model is a design decision.
Why Nonhuman Primates Are Used For siRNA DMPK
Nonhuman primates are the closest relatives of humans in genetics, anatomy, physiology, immunology, and behavior. They share metabolic pathways, organ systems, disease susceptibility, and immune responses with humans to a degree that rodents do not, so Pharmacokinetics (PK) data from a monkey study translate with fewer assumptions attached. Nonhuman primates also help researchers address ethical and regulatory issues that may arise from using human subjects or tissues for siRNA research.
That is why Nonhuman primate DMPK research has become the reference setting for oligonucleotide programs needing tissue-level exposure.
What NHP Work Adds To siRNA Development
Nonhuman primate DMPK research can change siRNA development in several applications:
- Improving the delivery and biodistribution of siRNA molecules
- Enhancing the stability and efficacy of siRNA molecules
- Reducing the off-target effects and toxicity of siRNA molecules
- Developing novel siRNA-based therapies for various diseases and disorders
Biodistribution is read by imaging or tissue counting after a labelled dose, which is what a Biodistribution Imaging Service covers. Exposure and stability come from serial sampling, and for molecules delivered into cerebrospinal fluid that means CSF draws alongside plasma, as in the NHP Intrathecal Dosing & CSF Sampling Services workflow. Toxicity and off-target effects need an effect readout rather than an exposure one, which is the Pharmacodynamics (PD) half of the question.
Evidence From NHP siRNA Studies
Several nonhuman primate experiments have moved siRNA research forward. Researchers at the David H. Koch Institute for Integrative Cancer Research at MIT achieved efficient gene silencing in the endothelium of nonhuman primates by delivering small interfering RNA (siRNA) with 7C1, a low-molecular weight, ionizable polymer that forms nanoparticles. In another study, lipid-nanoparticle-encapsulated short interfering RNAs (siRNAs) rapidly adapted to target the Makona outbreak strain of Ebola virus protected every rhesus monkey in the study against lethal challenge when treatment was initiated at 3 days after exposure, while animals were viraemic and clinically ill.
Both examples rest on the same foundation: a dose that reached the right tissue and stayed long enough. Prisys Biotech runs siRNA and oligonucleotide studies across its NHP Pharmacology platform and its NHP(monkey) Disease Models portfolio, reading exposure, distribution, and pharmacology from the same animals.
